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Changes in the state of a cell as it responds to signals de-
livered by soluble mediators as well as by engagement of
ligands displayed on cell surfaces or on extracellular matri-
ces are the basis of differentiation, development, and the
activation of effector functions. The molecular mechanisms
by which ligands of cell surface receptors elicit such
changes occupy not only a large proportion of the time and
interest of cell and molecular biologists, but also account
for an extensive fraction of the prokaryotic and eukaryotic
genomes and proteomes. Complex systems that lend them-
selves to a deep analysis of such cell-signaling events in-
clude the network by which the immune system commu-
nicates within and among its major components: T cells, B
cells, NK cells, and APCs. The study of T cells and the
means of their activation have been augmented by our un-
derstanding of the primary sensor of the activating signal,
the multichain TCR complex, which consists of an MHC/
 
peptide-specific 
 
   
 
receptor, CD3 
 
   
 
and 
 
   
 
hetero-
dimers, and the 
 
   
 
homodimer (1). Here, ligand recogni-
tion is concentrated in the 
 
   
 
pair, and signal transduction
results from structural modification (phosphorylation) of
specific tyrosine residues in the cytoplasmic domains of 
 
 
 
,
 
 
 
, 
 
 
 
, and 
 
 
 
. In addition, accessory molecules (CD4 and
CD8) and costimulatory molecules (CD28) may properly
be considered components of the complete signaling ma-
chinery (2–5). Interest in CD28 as well as its inhibitory ho-
mologue, CTLA-4, has been bolstered not only by a fun-
damental quest for the rules that govern complex signaling
pathways, but also by the attractive likelihood that these
molecules might well serve as targets for pharmacological
intervention to augment immunotherapy for tumors and
infections, or to temper autoimmune events that contribute
to a host of acute and chronic diseases (6, 7).
The most recent of a series of investigations on the
mechanism of CD28-mediated costimulation, based pri-
marily on the detailed characterization of a number of anti-
CD28 mAbs, reported by Lühder et al. (8) in this issue, not
only offers insight into a means for stimulating T cells via a
pathway that bypasses the TCR, but also illuminates the
molecular mechanism by which ligation of CD28 leads to
activation, lends support to other recent studies on the stoi-
chiometry and affinity of CD28–ligand interactions (9), and
raises the possibility that conformational alternatives of
 
CD28 structure may contribute to the transduction of
differential signals.
Under physiological conditions, optimal activation of a
mature resting T lymphocyte requires that its clonally ex-
pressed 
 
   
 
TCR bind its complementary MHC/peptide
complex as a primary signal (known as “signal 1”) and also
that its CD28 molecule bind a ligand, CD80 or CD86
(otherwise known as B7-1 and B7-2, respectively), as “sig-
nal 2” (10). Engagement of the 
 
   
 
TCR in the absence of
CD28 engagement results in a failure to fully activate the T
cell, but also, for naive cells, may lead to a state of T cell
unresponsiveness (11). Under controlled experimental con-
ditions, immunologists frequently substitute mAbs directed
against the TCR complex to replace the MHC/peptide
ligand as signal 1. Similarly, signal 2 can be mimicked by
engagement of CD28 with a suitable mAb directed against
this cell surface signal transducer.
The novel results reported by Lühder et al. (8) derive
initially from a set of mAbs raised in the mouse against rat
CD28 (12). Characterized functionally, these mAbs fall
into two groups: (a) those mAbs that provide the costimu-
lation to T cells concomitantly exposed to a TCR-medi-
ated signal (called by the authors “conventional” mAb),
and (b) those mAbs (designated “superagonistic”) that fully
activate primary resting T cells both in vivo and in vitro in
the absence of signal 1. Because they were raised in the
mouse against rat molecules, which differ at only nine posi-
tions in the exposed part of the molecule, these antibodies
must be focused on surface epitopes defined by these differ-
ences. By straightforward engineering of recombinant chi-
meric and mutant CD28 molecules, and analysis of their
antibody reactivity after expression in L929 cells, the pre-
cise location of the residues in the linear sequence of the rat
CD28 was mapped. The conventional antibodies were fo-
cused on a region around phenylalanine residue 98, which
lies adjacent to the highly conserved “MYPPPY” loop
found in both CD28 and CTLA-4. The superagonist anti-
bodies localized to residues on what is known as the C”D
loop, comprising amino acids 60–65. These results were
strengthened by the observation that the reactivity of a
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conventional hamster anti–mouse mAb was lost with the
mutation at position 98. Although the X-ray structure of
CD28 has not yet been solved, structures have been deter-
mined of mouse (13) and human (14) CTLA-4 and of hu-
man CTLA-4 in complex with both CD80 (B7-1; refer-
ence 15) and CD86 (B7-2; reference 16). CTLA-4, and by
homology, CD28, contain a single Ig-like Ig V set domain
linked to transmembrane and cytoplasmic domains. Amino
acid identity in the extracellular Ig-like domains of CD28
and CTLA-4 is sufficient to allow precise sequence align-
ment and the generation of a respectable molecular model
of the CD28 monomer (8, 17). Thus, the sites on the mo-
lecular surface of CD28 that define the focus of the two
different groups of antibodies can be located. The C”D
loop, on which the superagonist mAbs are focused, lies
proximal to the cell surface and seems inaccessible for large
ligands whereas the MYPPPY loop, which has been con-
firmed to be the precise site of B7 (CD80/CD86) binding
in the crystal structure of the two different CTLA-4/B7-1
(15) and B7-2 (16) complexes, lies at the tips of an anti-
body-like “Y” poised for interaction with CD80/CD86
ligands and cross-linking (illustrated schematically in Fig.
1). The consistent observation that the site of the epitope
dictates the functional outcome of mAb binding is further
underlined by identification of anti–human CD28 mAbs
that fall into the same categories. Mouse CD28 molecules
with grafted rat or human C”D sequences expressed in a T
cell transfection system showed the predicted functionality:
they contributed a superagonist signal when expected. Fi-
nally, the biochemical product of superagonist signaling
was evaluated in the human cell system. Costimulation of
TCR with anti-CD28 conventional mAb resulted in phos-
phorylation of both ZAP-70 and 
 
  
 
as expected whereas su-
peragonist stimulation bypassed the proximal TCR signal-
ing but resulted in activation of the nuclear factor 
 
 
 
B
family, leading to nuclear translocation of c-Rel and p50.
 
Recent results examining the stoichiometry, kinetics,
and affinities of the CTLA-4 and CD28 interactions with
CD80 (B7-1) and CD86 (B7-2; reference 9) as well as an
expanding understanding of the mobilization of TCR and
costimulatory molecules to a distinct membrane domain
known as the central supramolecular activation complex
(c-SMAC; reference 18), suggest several models to explain
how ligation of a CD28 in one topological orientation may
give rise to a cellular signal distinct from that elicited when
bound in a second orientation.
First, we need to review the most crucial results of the
recent experiments. Collins et al. (9) demonstrate that de-
spite the homodimeric structure of CD28, it interacts with
both B7-1 and B7-2 as though it has a single binding site.
Thus, it is functionally monovalent. B7-2, a monomer with
only one binding site for either CD28 or CTLA-4, is in-
duced on the APC early in the immune response. There-
fore, the earliest interaction is of the dimeric but monova-
lent CD28, with the monomeric B7-2. This is an
interaction of modest affinity and thus might be assumed to
offer a modest costimulatory signal. As the immune re-
sponse proceeds, B7-1 on the APC and CTLA-4 on the
responding T cell, are expressed after 
 
 
 
24–48 h. B7-1
seems to be in a monomer–dimer equilibrium at the APC
surface, permitting maintenance of the CD28 signal and
perhaps even a more powerful signal (assuming that the
measured affinities read out more or less directly as the
strength of signal) results. Concomitant with the B7-1 in-
duction on the APC, the T cell expresses its inhibitory
CD28 analogue, CTLA-4, which not only has a higher af-
finity for the B7-2 ligand expressed earlier and therefore
may effectively compete for binding there, but also has an
even higher affinity for B7-1. The salient features of the
stoichiometry and affinity measurements are that CD28 in-
teracts essentially monovalently with B7-2 early in the re-
sponse and that the later B7-1 interaction may cause some
Figure 1. Location of sites of in-
teraction of CD80 (B7-1) and CD86
(B7-2) and of superagonist mAbs
mapped to the surface of CD28. The
structure of CD28 as a disulfide-
linked Ig-like homodimeric domain
on the surface of the T cell is illus-
trated schematically, depicting inter-
actions with either the monomeric
B7-2 or the homodimeric B7-1.
The surface exposure the MYPPPY
loop that has been shown crystallo-
graphically to interact with both
B7-2 and B7-1 is colored red and
the C”D loop that interacts with the
superagonistic antibodies is shown in
yellow. The cytoplasmic carboxyl-
terminus of CD28 is indicated and
the potential phosphorylation site(s)
is indicated as a green circle.T
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forced dimerization of the CD28 monovalent dimers, but
does not cross-link CD28 further. The inherently divalent
CTLA-4 interactions, both with monomeric B7-2 and
dimeric B7-1, provide a clear explanation for predomi-
nance of the later CTLA-4–driven inhibition of the T cell.
The role of CD28 with respect to the physical reorgani-
zation of the c-SMAC is somewhat controversial, with sev-
eral reports indicating the importance of CD28 in the tem-
poral reorganization of the TCR and the late persistence of
kinases (lck and PKC-
 
 
 
) in the immunological synapse (19,
20), and some suggesting that raft accumulation is indepen-
dent of CD28 costimulation (21). For the purposes of the
model described below, I will take the view that CD28
plays a role in the c-SMAC and contributes to more stable
and prolonged activation.
How can we explain the clear-cut correlation of epitope
mapping and functional outcome of the two different
classes of anti-CD28 mAbs? Lühder et al. (8) lay out four
possible models, succinctly described as: preferential en-
gagement of signaling-competent CD28, differential cross-
linking, proximity effects, and antibody-induced confor-
mational changes. They favor a model that bivalent binding
and lattice formation of CD28 by the superagonist antibod-
ies forms an array distinct from that formed by the interac-
tion of CD28 with B7-2 and B7-1 and this therefore deliv-
ers a stronger signal.
I think that it is helpful to consider the differential effects
of the two classes of mAbs not only in terms of their ability
to cross-link, but also in terms of the possibility that they
stabilize two distinct conformations of the CD28 ho-
modimer. First, we hypothesize that the CD28 molecule, a
disulfide-linked covalent dimer, has the structural flexibility
to dimerize in two different conformations that are in dy-
namic equilibrium with each other. One dimeric form is
“relaxed” and the other “parallel.” The relaxed form has a
dimeric structure that mimics the known structure of
CTLA-4, with the MYPPPY B7 binding loops available at
the tips of the Y. The parallel form provides a structure
akin to an antibody or TCR Fv, with the MYPPPY loops
away from the cell membrane, but each loop so close to its
dimeric partner as to preclude divalent binding by B7. In
the relaxed conformation the cytoplasmic tail of the mole-
cule is largely unavailable for interaction with other mole-
cules, such as kinases lck and PI-3 kinase, or the SH2 adap-
tor protein, GRB-2 (22). Although the precise sequence of
activation events conveyed by CD28 ligation remains an-
other controversial area, I would take the view that the
COOH-terminal cytoplasmic proline-rich region of CD28
is mobilized by interactions of the extracellular domain
with either B7 or antibodies, that this first interacts with an
SH3 domain of a kinase such as lck (23), which then con-
tributes to the phosphorylation of the tyrosine of the
YMNM sequence of the CD28 cytoplasmic domain. The
phospho YMNM sequence is then available for the wide
variety of molecular interactions known for CD28, includ-
ing those with PI-3 kinase, GRB-2, and ITK.
How then can we account for the different signals deliv-
ered by the different sets of anti-CD28 mAbs? Some in-
sight can be gained by consideration of popular models for
transmembrane signaling, best articulated by Ottemann et
al. (24) in their discussion of the mechanism of action of
the aspartate receptor. They described five possible models:
association/dissociation, piston, rotation, scissor, and see-
saw, by which ligation of the extracellular domains of a
Figure 2. A differential con-
formation model for CD28-medi-
ated conventional and superag-
onist signaling. The unliganded
disposition of the hypothesized
relaxed (A) and parallel (B) con-
formations of CD28 is indicated.
Color coding of interacting sites
is as in Fig. 1. The conventional
or costimulatory binding of B7-2
to CD28 results in the liberation
of the carboxylterminus of
CD28, making this proline-rich
domain available for SH3 do-
main interaction. This would re-
sult in the kinase-dependent
phosphorylation of the potential
PI3-kinase, GRB-2, and ITK
binding site (C). Drawn approxi-
mately to scale, the binding of a
full antibody to the C”D super-
agonist site promotes the more
complete liberation of the cyto-
plasmic domains of CD28, mak-
ing them more available for both
SH3 and kinase and adaptor in-
teraction (D).T
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simple dimeric receptor could change the topological rela-
tionships of the cytoplasmic domains ultimately leading to
changes in associated enzymatic activities. They argued,
based on electron proton resonance spectra of molecules
spin labeled at strategic positions, that the aspartate receptor
exploits the piston model. Recent crystallographic evi-
dence suggests that a screw-like movement involving both
rotational and piston movement (of 
 
 
 
1.6 Å) might be in-
volved in a similar receptor, the microbial light sensory
rhodopsin (25). Although the covalent disulfide bond that
stabilizes the CD28 homodimer may limit aspects of the
molecular motion that might be transduced from extracel-
lular ligation of the molecule, this may not preclude
changes in the exposure of the cytoplasmic domain depen-
dent on either lattice formation or lipid environment. A
model for 
 
 
 
-mediated signaling based on differential expo-
sure of cytoplasmic phosphorylation sites in different lipid
microenvironments is relevant here (26), because 
 
  
 
too is a
disulfide-linked covalent dimer.
Therefore, our best model is illustrated in Fig. 2. The
binding of the relaxed form of the CD28 homodimer by
B7 or by conventional mAbs causes a sufficient perturba-
tion of the cytoplasmic domain to allow the carboxylter-
minal peptide to be exposed to the SH3 domain of a ki-
nase such as lck. For the sake of argument, I would favor a
“piston” model as described above (24). In the context of
TCR ligation, where lck is juxtaposed to the TCR com-
plex by its interaction with CD4 or CD8, the activated lck
may then initiate phosphorylation of the YMNM tyrosine
of the CD28 cytoplasmic domain. This then becomes the
focus for the dynamic cascade of subsequent signaling
events. The binding of the superagonist antibodies, by
forcing a greater perturbation of the cytoplasmic domain
through the transmitted effect, perhaps by a scissors model
and enforced by the greater spatial distribution of CD28
resulting from the 
 
 
 
150 Å distance from the first to the
second binding site of mouse IgG1 (27), releases the mem-
brane-associated domain from a sequested to an available
conformation, results in a more accessible, and thus more
active CD28. This might function in the absence of TCR
signal 1 by interactions of the carboxylterminal peptide
with the SH3 domain of a kinase other than lck. One fea-
ture of this model that is inconsistent with available data is
that it proposes both a bivalent and a monovalent form of
the CD28 homodimer for B7 or conventional antibody li-
gation. The data of Collins et al. (9) indicate that the re-
combinant form of CD28 is monovalent. Perhaps the cell
surface form may reveal two conformations. Tests of the
model lie in further exploration of the signaling interme-
diates that result from the two kinds of antibodies, and in
the determination of the CD28 structure and further clari-
fication of its dimerization and valency properties. One
additional prediction of the model is that physiological
ligands that bind the C”D site other than the superagonist
mAb exist and play a functional role in vivo. Perhaps these
have been overlooked because they play an infrequent or
minor role. The stage is set for more experiments. Let the
play begin.
 
I thank I. Stefanova and the members of my laboratory for com-
ments and discussion.
 
Submitted: 24 February 2003
Accepted: 27 February 2003
 
References
 
1. Call, M.E., J. Pyrdol, M. Wiedmann, and K.W. Wuch-
erpfennig. 2002. The organizing principle in the formation of
the T cell receptor-CD3 complex. 
 
Cell.
 
 111:967–979.
2. Alegre, M.L., K.A. Frauwirth, and C.B. Thompson. 2001.
T-cell regulation by CD28 and CTLA-4. 
 
Nat. Rev. Immunol.
 
1:220–228.
3. Blair, P.J., J.L. Riley, R.G. Carroll, D.C. St. Louis, B.L. Le-
vine, B. Saha, K.P. Lee, P.J. Perrin, D.M. Harlan, and C.H.
June. 1997. CD28 co-receptor signal transduction in T-cell
activation. 
 
Biochem. Soc. Trans.
 
 25:651–657.
4. Frauwirth, K.A., and C.B. Thompson. 2002. Activation and
inhibition of lymphocytes by costimulation. 
 
J. Clin. Invest.
 
109:295–299.
5. Salomon, B., and J.A. Bluestone. 2001. Complexities of
CD28/B7: CTLA-4 costimulatory pathways in autoimmu-
nity and transplantation. 
 
Annu. Rev. Immunol.
 
 19:225–252.
6. Egen, J.G., M.S. Kuhns, and J.P. Allison. 2002. CTLA-4:
new insights into its biological function and use in tumor im-
munotherapy. 
 
Nat. Immunol.
 
 3:611–618.
7. Alegre, M., F. Fallarino, P. Zhou, K. Frauwirth, J. Thistle-
thwaite, K. Newell, T. Gajewski, and J. Bluestone. 2001.
Transplantation and the CD28/CTLA4/B7 pathway. 
 
Trans-
plant. Proc.
 
 33:209–211.
8. Lühder, F., Y. Huang, K.M. Dennehy, C. Guntermann, I.
Müller, E. Winkler, T. Kerkau, S. Ikemizu, S.J. Davis, T.
Hanke, et al. 2003. Topological requirements and signaling
properties of T cell–activating, anti-CD28 antibody superag-
onists. 
 
J. Exp. Med
 
. 197:955–966.
9. Collins, A.V., D.W. Brodie, R.J. Gilbert, A. Iaboni, R.
Manso-Sancho, B. Walse, D.I. Stuart, P.A. van der Merwe,
and S.J. Davis. 2002. The interaction properties of costimula-
tory molecules revisited. 
 
Immunity.
 
 17:201–210.
10. Schwartz, R.H. 1992. Costimulation of T lymphocytes: the
role of CD28, CTLA-4, and B7/BB1 in interleukin-2 pro-
duction and immunotherapy. 
 
Cell.
 
 71:1065–1068.
11. Schwartz, R.H. 1997. T cell clonal anergy. 
 
Curr. Opin. Im-
munol.
 
 9:351–357.
12. Tacke, M., G. Hanke, T. Hanke, and T. Hunig. 1997.
CD28-mediated induction of proliferation in resting T cells
in vitro and in vivo without engagement of the T cell recep-
tor: evidence for functionally distinct forms of CD28. 
 
Eur. J.
Immunol.
 
 27:239–247.
13. Ostrov, D.A., W. Shi, J.C. Schwartz, S.C. Almo, and S.G.
Nathenson. 2000. Structure of murine CTLA-4 and its role
in modulating T cell responsiveness. 
 
Science.
 
 290:816–819.
14. Metzler, W.J., J. Bajorath, W. Fenderson, S.Y. Shaw, K.L.
Constantine, J. Naemura, G. Leytze, R.J. Peach, T.B.
Lavoie, L. Mueller, et al. 1997. Solution structure of human
CTLA-4 and delineation of a CD80/CD86 binding site con-
served in CD28. 
 
Nat. Struct. Biol.
 
 4:527–531.
15. Stamper, C.C., Y. Zhang, J.F. Tobin, D.V. Erbe, S. Ikemizu,
S.J. Davis, M.L. Stahl, J. Seehra, W.S. Somers, and L. Mo-
syak. 2001. Crystal structure of the B7-1/CTLA-4 complex
that inhibits human immune responses. 
 
Nature.
 
 410:608–611.
16. Schwartz, J.C., X. Zhang, A.A. Fedorov, S.G. Nathenson,T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
953
 
Margulies
and S.C. Almo. 2001. Structural basis for co-stimulation by
the human CTLA-4/B7-2 complex. 
 
Nature.
 
 410:604–608.
17. Bajorath, J., W.J. Metzler, and P.S. Linsley. 1997. Molecular
modeling of CD28 and three-dimensional analysis of residue
conservation in the CD28/CD152 family. 
 
J. Mol. Graph.
Model.
 
 15:135–139, 108–111.
18. Monks, C.R., B.A. Freiberg, H. Kupfer, N. Sciaky, and A.
Kupfer. 1998. Three-dimensional segregation of supramolec-
ular activation clusters in T cells. 
 
Nature
 
. 395:82–86.
19. Viola, A., S. Schroeder, Y. Sakakibara, and A. Lanzavecchia.
1999. T lymphocyte costimulation mediated by reorganiza-
tion of membrane microdomains. 
 
Science.
 
 283:680–682.
20. Huang, J., P.F. Lo, T. Zal, N.R. Gascoigne, B.A. Smith,
S.D. Levin, and H.M. Grey. 2002. CD28 plays a critical role
in the segregation of PKC theta within the immunologic syn-
apse. 
 
Proc. Natl. Acad. Sci. USA.
 
 99:9369–9373.
21. Burack, W.R., K.H. Lee, A.D. Holdorf, M.L. Dustin, and
A.S. Shaw. 2002. Cutting edge: quantitative imaging of raft
accumulation in the immunological synapse. 
 
J. Immunol.
 
 169:
2837–2841.
22. Rudd, C.E. 1996. Upstream-downstream: CD28 cosignaling
pathways and T cell function. 
 
Immunity.
 
 4:527–534.
23. Holdorf, A.D., J.M. Green, S.D. Levin, M.F. Denny, D.B.
Straus, V. Link, P.S. Changelian, P.M. Allen, and A.S. Shaw.
1999. Proline residues in CD28 and the Src homology (SH)3
domain of Lck are required for T cell costimulation. 
 
J. Exp.
Med.
 
 190:375–384.
24. Ottemann, K.M., W. Xiao, Y.K. Shin, and D.E. Koshland,
Jr. 1999. A piston model for transmembrane signaling of the
aspartate receptor. 
 
Science.
 
 285:1751–1754.
25. Gordeliy, V.I., J. Labahn, R. Moukhametzianov, R. Efre-
mov, J. Granzin, R. Schlesinger, G. Buldt, T. Savopol, A.J.
Scheidig, J.P. Klare, et al. 2002. Molecular basis of trans-
membrane signalling by sensory rhodopsin II-transducer
complex. 
 
Nature.
 
 419:484–487.
26. Aivazian, D., and L.J. Stern. 2000. Phosphorylation of T cell
receptor zeta is regulated by a lipid dependent folding transi-
tion. 
 
Nat. Struct. Biol.
 
 7:1023–1026.
27. Harris, L.J., E. Skaletsky, and A. McPherson. 1998. Crystallo-
graphic structure of an intact IgG1 monoclonal antibody. 
 
J.
Mol. Biol.
 
 275:861–872.